Purespring Therapeutics has raised $105m in a Series B funding round which will help progress its lead candidate PS-002 to ...

London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of ...

Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for diseases of the kidney.

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseasesOversubscribed financing led ...

Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to ...

Our round-up of recent biotech financings features a strong first round for City Therapeutics, a new RNAi venture led by ...

Purespring raises £80 million in a Series B financing, with Syncona committing £19.9 million[1] as part of a leading syndicate of life science investorsProceeds will be used to advance Purespring’s ...

Purespring Therapeutics, a UK-based gene therapy company focused on kidney disease, has raised £80 million ($105 million) in ...

The London-based firm said it will use the funds to advance its gene therapy pipeline, including its lead program in IgA nephropathy.

Life science investor Syncona said its portfolio company Purespring Therapeutics, which focuses on gene therapies for kidney diseases, had raised £80m in an oversubscribed financing.

A University of Bristol spinout company focused on transforming the way kidney diseases are treated has announced an £80m ...

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases ...